OrbusNeich

Latest Data Shows OrbusNeich's COMBO(TM) Dual Therapy Stent has Excellent Healing Benefits

Washington (ots/PRNewswire) - The world's first and only dual therapy stent

Prof. Stephen W.L. Lee presented two-year optical coherence tomography (OCT) findings and three-year clinical follow up from the EGO COMBO study, providing further evidence to support the healing benefits of the COMBO Dual Therapy Stent, the only drug eluting stent (DES) with active EPC capture technology.

The findings were presented during the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, held in Washington, D.C., September 13-17, 2014.

"This is the first study to assess the healing profile of a dual therapy stent by optical coherence tomography," said Prof. Stephen W.L. Lee, M.D., of the Queen Mary Hospital, Hong Kong. "The COMBO Stent's unique approach shows early healing benefits and stability over the long-term. The results demonstrate no neoatherosclerosis observed by OCT at 24 months, and no late restenosis or stent thrombosis beyond 36 months. The COMBO Stent is the only DES which exhibits neointima regression from 9 months to 24 months. This is an indication of true vessel healing."

Latest evidence surrounding the COMBO Stent's active EPC capture was also presented by Prof. Michael Haude, M.D., Lukaskrankenhaus, Neuss, Germany, and President-Elect of the EAPCI, who demonstrated how the COMBO Stent uses a bound antibody to capture EPCs and promotes accelerated endothelial coverage.

"The COMBO Stent sets a new standard for stenting," said Prof. Haude. "With the dual therapy approach of the COMBO Stent, the abluminal sirolimus release from a bioresorbable polymer matrix controls the restenosis and neointimal proliferation, whilst the luminal surface is coated with an antibody that enables an earlier and more mature healing of the stented lesion. Delayed healing is of continued concern in conventional DES today as it leads to stent thrombosis and, in the long-term, to neoatherosclerosis. The COMBO Stent helps to address these concerns and may offer a long-term solution."

About the COMBO Dual Therapy Stent

The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that is completely dissipated within 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous(TM) Stent. Other products include stents and balloons marketed under the names of Azule(TM), R Stent(TM), Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Follow OrbusNeich on Twitter at http://www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Contact:

Global Media Contacts: Cheryl Pitcher, +44(0)78-09-492-191,
cheryl.pitcher@fleishmaneurope.com, Iva Ng, OrbusNeich,
+852-3109-7268,
ing@orbusneich.com
Original-Content von: OrbusNeich, übermittelt durch news aktuell

Das könnte Sie auch interessieren: